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ABSTRACT  1 
Chronic wounds cause significant patient morbidity and mortality. A key factor in their 2 
etiology is microbial infection, yet skin host-microbiota interactions during wound repair 3 
remain poorly understood. We investigated microbiome profiles of non-infected human 4 
chronic wounds and showed that reduced diversity was associated with subsequent healing 5 
outcome. Furthermore, poor clinical healing outcome was associated with increased local 6 
expression of the pattern recognition receptor NOD2. To investigate NOD2 function in the 7 
context of cutaneous healing, we treated mice with the NOD2 ligand muramyl dipeptide (MDP) 8 
and analyzed wound repair parameters and expression of anti-microbial peptides. MDP 9 
treatment of littermate controls significantly delayed wound repair associated with reduced re-10 
epithelialization, heightened inflammation and upregulation of murine β-Defensins (mBD) 1, 11 
3 and particularly 14. We postulated that although BD14 might impact on local skin microbial 12 
communities it may further impact other healing parameters. Indeed, exogenously administered 13 
mBD14 directly delayed mouse primary keratinocyte scratch wound closure in vitro. To further 14 
explore the role of mBD14 in wound repair, we employed Defb14-/- mice, and showed they had 15 
a global delay in healing in vivo, associated with alterations in wound microbiota. Taken 16 
together these studies suggest a key role for NOD2-mediated regulation of local skin 17 
microbiota which in turn impacts on chronic wound etiology.   18 
  19 
 20 
 21 
22 
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INTRODUCTION 1 
Chronic wounds, which include pressure sores, venous and diabetic foot ulcers (DFUs), are a 2 
global problem leading to substantial morbidity and mortality (Gottrup, 2004).  Following 3 
injury, skin-resident microbiota and pathogenic species may colonise the wound and proliferate 4 
(Eming et al., 2014). Hence understanding the role of bacteria, both pathogenic and 5 
commensal, in the context of skin wounding is important yet comparatively little research 6 
attention has focused on this area (Loesche et al., 2017, Misic et al., 2014).  7 
 8 
Poor progression of chronic wounds is often associated with infection and the presence of 9 
recalcitrant microbial biofilms comprising Staphylococcus, Pseudomonas and 10 
Corynebacterium and a variety of other organisms (Attinger and Wolcott, 2012, James et al., 11 
2008, Mancl et al., 2013, Rhoads et al., 2012). The innate immune system detects infection and 12 
injury via pattern recognition receptors (PRRs), such as the Nod-like receptors. PRRs respond 13 
to highly conserved microbial structures- pathogen-associated molecular patterns that can 14 
trigger inflammatory and defense responses such as keratinocyte-mediated production of anti-15 
microbial peptides (AMPs). AMPs provide rapid and efficient anti-microbial activity against a 16 
wide range of pathogens (Dutta and Das, 2016, Harder et al., 2013). The skin has many AMPs 17 
including Cathelicidins, β-defensins, S100A15, RNase-7 and Histones (Buchau et al., 2007, 18 
Dorschner et al., 2001, Gallo and Hooper, 2012, Halverson et al., 2015, Simanski et al., 2010, 19 
Sorensen et al., 2006, Yang et al., 2017) and induces members of the β-defensin family under 20 
conditions of inflammation, infection and wound healing (Mangoni et al., 2016, Schneider et 21 
al., 2005) .  22 
 23 
Several pivotal studies have provided insight into the host response during cutaneous wound 24 
repair (Campbell et al., 2013, Grice et al., 2010) yet relatively little is known about the skin 25 
 4 
 
microbiota and whether they have detrimental or beneficial impacts on repair. Here, we 1 
demonstrate an association between the bacterial profile of non-infected human DFUs and 2 
healing outcome, correlating with upregulated expression of the PRR NOD2. Using both 3 
NOD2 stimulated and Defb14 null murine models we reveal new insights into the role of the 4 
innate defense response in controlling the skin microbiota during wound repair. 5 
 6 
RESULTS 7 
Human chronic wound microbiome is linked to healing outcome 8 
Patients were recruited with chronic non-infected DFUs (Grade A1/B1, no infection or 9 
ischemia at the time of presentation). Total eubacterial diversity was profiled using 16S PCR-10 
Density Gradient Gel Electrophoresis (16S PCR-DGGE) on DFU punch biopsy tissue collected 11 
at clinical presentation (week 0). Patients were then separated into two groups according to 12 
their time to heal over a period of 12 weeks; DFU healed ≤7 weeks (n = 10) versus non-healed 13 
≥12 weeks (n = 9). Eubacterial DNA profiles (UPGMA dendrogram) at presentation (week 0) 14 
showed clear segregation between wounds that would heal versus those that would not (Figure 15 
1a; wound closure at ≤7 weeks (green) versus ≥12 weeks (purple), n = 19). 16S rRNA Illumina 16 
high-throughput sequencing of a further set of DFU samples (n = 25) and non-metric multi-17 
dimensional analysis (NMDS) showed no clear separation between the microbial profiles of 18 
the healed compared to the non-healed wounds (Figure 1b); however, non-healing wounds 19 
were associated with significantly reduced overall phylum diversity (Figure 1c). Phylum level 20 
relative abundance was consistent between healed and non-healed wounds (Fig 1d); however, 21 
interestingly genus level taxonomic classification of the wound microbiome revealed a 22 
significantly altered microbial community in healed versus non-healed wounds, including 23 
relative abundance variation within common skin-associated taxa such as Staphylococcus (23% 24 
in healed wounds versus 19% in non-healing wounds), Anaerococcus (3% in healed wounds 25 
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versus 10% in non-healing wounds) and Coprococcus (classified in other genera category, 1 
Figure 1e (P=<0.05)). The taxonomic information for all mapped reads at the genus level can 2 
be found in the supplementary material (Table S2). Finally, the overall presence of bacteria in 3 
wounds was assessed by direct Gram stain of DFU biopsy tissue which revealed no significant 4 
difference in bacterial numbers between the groups (Figure 1f-g). Collectively this data 5 
suggests that bacterial community diversity rather than overall bacterial burden correlates with 6 
DFU healing outcome.  7 
 8 
NOD2 is upregulated in human chronic wounds that fail to heal 9 
We next assessed whether PRR expression was altered as PRRs have been implicated in the 10 
skin microbiome regulation (Campbelle t al., 2013, Dasu et al., 2010, Lai et al., 2009, Lin et 11 
al., 2012). Several TLRs trended towards increased expression in non-healing wounds (Figure 12 
2a-e) but only the intracellular PRR NOD2 was significantly increased (P<0.05, Figure 2f). 13 
NOD2 is implicated in barrier function, epithelial turnover and repair (Cruickshank et al., 2008) 14 
therefore we investigated NOD2 function in keratinocytes. Keratinocyte scratch wound closure 15 
was significantly reduced following treatment with the NOD2 ligand, MDP (P<0.05, Figure 16 
2g-h). Scratch closure was also inhibited by a range of TLR ligands (Figure S1a); however, 17 
TLR2 ligands did not affect closure. The addition of mitomycin C to inhibit proliferation 18 
(Figure 2h) showed no difference in migration between MDP treatment and control, 19 
implicating NOD2 signalling in the proliferative component of scratch wound closure. qPCR 20 
confirmed that MDP treatment significantly increased keratinocyte mRNA expression of 21 
NOD2 (P<0.05, Figure 2i). 22 
 23 
Experimental stimulation of the NOD2 pathway delays cutaneous wound healing 24 
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We next investigated the impact of NOD2 activation using C57BL/6 mice subcutaneously 1 
injected with MDP or vehicle control, prior to incisional wounding. MDP treatment 2 
upregulated Nod2 mRNA in the wound (Figure S1b) and showed a trend for upregulation of 3 
the Nod2 associated downstream signalling molecules Rip2 but not Tak1, (Figure S1c-d). MDP 4 
treatment significantly delayed wound closure (Figure 3a) demonstrated by increased 5 
histological wound area (P<0.001, Figure 3b) and reduced re-epithelialization (P<0.01, Figure 6 
3c). MDP-treated wounds had increased local wound recruitment of both neutrophils 7 
(P<0.001) and macrophages (P<0.01, Figure 3d-f) and we observed an extended keratinocyte 8 
activation response (extension of keratin 6 staining from the wound edge compared to control; 9 
P<0.01, Figure 3g-h). In line with these results, Ki67 staining in MDP treated wounds, 10 
demonstrated significantly increased wound edge proliferation in MDP-treated wounds (Figure 11 
3i-j). Collectively, these results demonstrate that MDP-mediated activation of NOD2 12 
significantly delays repair.  13 
 14 
NOD2 stimulation induces an anti-microbial response in cutaneous wound healing  15 
NOD2 has a known role in gut and lung epithelial AMP production specifically defensins 16 
(Rohrl et al., 2008, Tan et al., 2015). MDP treated wounds had significantly upregulated levels 17 
of mBD3 (P<0.05) and mBD14 (P<0.05) mRNA compared to control wounds (Figure 4a). 18 
Similarly, in vitro, MDP stimulated NHEKs significantly induced hBD1, hBD2 (the human 19 
orthologue to mBD3) and particularly hBD3 (the human orthologue to mBD14; P<0.05, Figure 20 
4b). We further explored the effect of mBD14 on wound healing, focusing on the keratinocyte 21 
response. We used a mBD14 peptide (Reynolds et al., 2010), which we confirmed as 22 
biologically active as it inhibited P. aeruginosa growth  (Figure S2a) and scratch-wounded 23 
primary mouse keratinocyte monolayers were treated with 1, 10 or 25 μg/ml of mBD14 24 
peptide. Keratinocyte migration was significantly decreased in a dose-dependent manner 25 
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(P<0.01, Figure 4c-d). Importantly, cell viability was unaffected by the peptide as determined 1 
by examination of morphological features, suggesting that mBD14 directly influences 2 
epidermal migration. The sequence homology between mBD14 and hBD3 is approximately 3 
69% (Hinrichsen et al., 2008, Rohrlet al., 2008), therefore we tested mBD14 peptide on human 4 
keratinocytes with similar results (Figure S2b).  We also investigated the impact of hBD3 on 5 
keratinocyte function using hBD3 transfected cells; however, we saw no effect on keratinocyte 6 
scratch closure (Figure S2c).  7 
 8 
β-defensin 14 null mice had delayed wound healing 9 
To further clarify the role of mBD14 we investigated excisional wound healing in mice that 10 
lack BD14 (Defb14-/-) and WT littermate controls. Histological analysis revealed delayed in 11 
wound repair in Defb14-/- mice (Figure 5a), with significantly increased wound area (P<0.01, 12 
Figure 5b) and delayed re-epithelialization (P<0.05, Figure 5c) at 3 days post-wounding. There 13 
was a significant reduction in neo-epidermal area although no difference in the distance 14 
contribution of keratin 6 expressing cells (P<0.05, Figure 5d-f).  Defb14-/- wounds had an 15 
extended epidermal proliferative response compared to control, with increased numbers of 16 
Ki67 expressing basal keratinocytes at the peri-wound edge (P<0.05, Figure 5g-h). 17 
Examination of the immune cells revealed no change in wound neutrophils (Figure 5i), but 18 
significantly increased macrophages suggesting altered immune response dynamics (P<0.01; 19 
Figure 5j). Defb14-/- wounds had increased wound granulation tissue iNOS+ cells (associated 20 
with classically activated macrophages) at 3 days post-wounding (P<0.01, Figure 5k), and a 21 
concomitant trend towards a decrease in Arg1+ cells  (expressed by alternatively activated 22 
macrophages) compared to controls (Figure 5l). Collectively, these data suggest an altered 23 
epidermal response and a highly pro-inflammatory local wound environment in the absence of  24 
β-defensin 14.  25 
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 1 
β-defensin 14 null mice have an altered wound bacterial profile  2 
Chronic wounds had altered communities of bacteria compared with wounds that healed well 3 
and we had shown that mBD14 peptide inhibited the growth of P. aeruginosa (Figure S2a) 4 
therefore, we assessed bacterial abundance in Defb14-/- mice. Total eubacterial abundance was 5 
significantly increased in Defb14-/- mice compared to controls as revealed by Gram-staining 6 
(P<0.01, Figure 6a-b) and 16S qPCR (P<0.05, Figure 6c). qPCR analysis of common skin 7 
bacterial species revealed increased levels of P. aeruginosa (P<0.01) as well as P. acnes 8 
(P<0.05, Figure 6d-g) implicating BD14 in a bacterial dysbiosis that is detrimental to healing.  9 
 10 
DISCUSSION  11 
Human skin is colonized by a diverse array of bacteria and microbes that generally live in 12 
harmony with the host, yet overgrowth of commensal species or pathogen infection can 13 
negatively impact healing (Grice and Segre, 2012a, 2012b). While the precise relationship 14 
between the microbes and healing remains unclear, diabetic wounds are thought to be colonized 15 
by distinct microbiota compared to normally healing wounds including increased 16 
Pseudomonas aeruginosa (Grice et al., 2010, Hinojosa et al., 2016, Price et al., 2011). 17 
However, not all wounds fail to heal and it remains unclear whether an altered skin microbiota 18 
is associated with a predisposition to delayed healing. The data presented here suggest that in 19 
the absence of clinical infection, microbiome profiles (and associated host response) play an 20 
important role in determining subsequent healing outcome. Thus, bacteria present on our skin 21 
prior to injury could dictate how we heal.   22 
 23 
In DFU patients, rather than the more "common" wound pathogens, we observed changes in 24 
genera abundance such as Corynebacterium, Enterococcaceae, and Helcococcus associated 25 
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with non-healing. We assessed the DFU microbiome at time of clinical presentation before the 1 
outcome of healing was known. Previous and complimentary longitudinal analysis of DFU-2 
associated bacteria have linked poor healing to a more stable microbiome, whereas wounds 3 
that healed well had a more dynamic microbiome that transitioned between community types 4 
(Loesche et al., 2017). Similarly, our findings implicate a less diverse microbiome at the 5 
initiation of healing, which may in turn impact upon the subsequent dynamics of the 6 
microbiome during healing. It remains unclear whether such observations will be broadly 7 
applicable to other wound types such as venous leg ulcers, decubitus ulcers and wounds that 8 
fail to heal by secondary intention. Studies do, however, suggest that neither patient 9 
demographics nor wound type exert major influence on the bacterial composition of the chronic 10 
wound microbiome (Wolcott et al., 2016).  11 
 12 
Several previous studies have shown that TLRs are differentially regulated when comparing 13 
acute wounds to chronic wounds, while a number of PRRs, such as TLR3, are important for 14 
wound chronicity (Campbell et al., 2013, Dasu et al., 2010, Lai et al., 2009, Lin et al., 2012). 15 
By contrast, our study tested PRR levels in longitudinally evaluated healing versus non-healing 16 
chronic wounds. In this context, the only PRR to show statistically significant alteration was 17 
NOD2. As the expression of NOD2 can be upregulated in response to bacterial ligation, it is 18 
plausible that the observed differential NOD2 levels in non-healing wounds may reflect a 19 
response to the differential bacterial composition of the wound environment.  20 
 21 
We further investigated the effect of experimentally activating NOD2 in a murine model, via 22 
the ligand muramyl dipeptide (MDP). Here MDP treatment led to a significant delay in healing. 23 
Studies have linked NOD2 dysregulation to an altered innate immune response, susceptibility 24 
to inflammation and delayed healing in acute wounds from elderly subjects (Hardman and 25 
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Ashcroft, 2008, Lesage et al., 2002). NOD2, but not TLR2, has an essential role during re-1 
epithelialisation following murine cutaneous injury (Campbell et al., 2013), and in the murine 2 
gut NOD2 regulates epithelial turnover and immune cell recruitment (Bowcutt et al., 2014, 3 
Cruickshank et al., 2008).  In the clinical setting, mutations in NOD2 are linked to the rare 4 
inflammatory skin condition Blau syndrome and delayed wound healing (Kurokawa et al., 5 
2003). Functional studies, have shown that both loss-of-function and gain-of-function 6 
mutations in NOD2 are associated with chronic inflammation (Kobayashi et al., 2005, 7 
Watanabe et al., 2004). This apparent dichotomy is thought to be because NOD2 can directly 8 
drive pro-inflammatory signals as well as inhibit other pathways such as the TLR2 mediated 9 
pathway of inflammation (Watanabe et al., 2004). Other research suggests that the ability of 10 
NOD2 to mediate a pro-inflammatory or anti-inflammatory effect is dependent upon the nature 11 
of accessory factors present, such as cytokines or bacterial products (Feerick and McKernan, 12 
2017). In this context, both NOD2 overexpression in human chronic wounds and Nod2 13 
stimulation in murine wounds is associated with delayed wound closure.  14 
 15 
NOD2 has a well-characterized role in the recognition and clearance of intracellular bacteria 16 
through activation of the pro-inflammatory pathway and other host defense pathways including 17 
AMPs (Philpott et al., 2014). In addition to anti-microbial roles (Hinrichsen et al., 2008), AMPs 18 
have been shown to modulate cytokine production (e.g. IL-1β, IL-22), keratinocyte migration 19 
and proliferation, and angiogenesis (Harder et al., 2013, Ong et al., 2002). MDP stimulation of 20 
NOD2 led to a significant upregulation of mBD3 and 14 (mouse orthologue of human hBD2 21 
and 3) in keratinocytes in vitro and wounded skin in vivo. Dysregulation of AMPs in the skin 22 
may be an important factor in the host susceptibility to bacterial colonization and wound repair.  23 
 24 
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Specific loss of Defb14 (mDB14) severely impaired multiple aspects of wound healing, with 1 
reduced re-epithelization, increased inflammation and a higher bacterial burden including P. 2 
aeruginosa, which we have previously shown to be detrimental to the healing response 3 
(Williams et al., 2017). These findings support previous observations that AMPs have diverse 4 
functions, including modulation of the innate immune system and altering TLR responsiveness 5 
(Beaumont et al., 2014, McGlasson et al., 2017, Semple et al., 2015, Wang et al., 2017). Some 6 
AMPS, such as cathelicidin, promote neutrophil recruitment and anti-microbial-activity and 7 
indeed Defb14-/- mouse wounds displayed limited neutrophil recruitment, despite delayed 8 
healing and a higher bacterial burden (Beaumont et al., 2014, Choi et al., 2012, Mookherjee 9 
and Hancock, 2007). The role of BD14 in keratinocytes is particularly poorly understood. Here 10 
we showed that treatment of in vitro keratinocyte scratch assays with mBD14 impaired scratch 11 
closure, although it remains unclear whether this is a direct effect or the result of activating 12 
other keratinocyte pro-repair pathways, such as local cytokine production (Wang et al., 2017). 13 
 14 
Collectively our work suggests that a greater knowledge of host microbial interactions is 15 
essential to understand wound healing progression. Bacterial ligands and anti-microbial factors 16 
are almost invariably multifactorial in function, conveying both beneficial and detrimental 17 
impacts on healing. Specifically, understanding the dynamics of host-microbial interactions 18 
will be key for better managing the treatment of patients with chronic wounds. In the future 19 
simple diagnostic tests to rapidly stratify healing potential based on wound bacterial 20 
composition will likely be coupled with bacteria-selective treatments and/or selective 21 
manipulation of the microbiome to promote healing. 22 
 23 
MATERIALS & METHODS 24 
Human chronic wounds 25 
 12 
 
Local ethical committee approval was obtained for all human studies, with informed consent 1 
obtained in accordance with the Declaration of Helsinki. 25 wound biopsy patient samples 2 
(mixed sex, aged ≥40 years) with chronic DFUs (defined as distal to the medial and lateral 3 
malleoli, with a known duration ≥4 weeks, grade A1/B1, University of Texas ulcer 4 
classification, no infection or ischaemia) were obtained at the time of presentation (week 0). 5 
All patients received standard-of-care treatment, including regular debridement, non-6 
antimicrobial dressing, and offloading. No local anaesthetic was used at any time during 7 
treatment. At week 0 wound biopsy samples were collected from the margin of DFUs prior to 8 
debridement using aseptic technique. Photographs of patient’s wounds were taken weekly over 9 
12 weeks to determine longitudinal healing outcome. DFUs were then separated into two 10 
groups, those who healed (full wound closure at ≤7 weeks; 10 patients) and those who failed 11 
to heal (wound not closed at 12 weeks; 9 patients) following current best practice treatment.   12 
 13 
Generation of hBD3 expressing HaCaT cell line 14 
A human Beta Defensin 3 stably over-expressing HaCaT cell line was constructed by 15 
transfecting cells with a plasmid containing hBD3 cloned into pcDNA3.1 (kind gift of Julia 16 
Dorin, University of Edinburgh). Lipofectamine 2000 (Life Technologies) was used for 17 
transfection as per manufacturer’s guidelines. Stably transfected cells were selected for by 18 
addition of 500µg/ml G418 (Life Technologies). Overexpression of hBD3 in the stable cell 19 
line compared to control vector transfected line was confirmed by Real Time PCR, using 20 
TaqMan primer probe to the coding region of hBD3 (Applied Biosystems, assay 21 
ID Hs04194486_g1).   22 
 23 
Cell culture and scratch migration assay 24 
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HaCaT cells (established human keratinocyte cell line) were cultured in DMEM plus 5% FBS. 1 
Normal human epidermal keratinocytes (NHEK) (PromoCell, Heidelberg, UK,) were cultured 2 
in Keratinocyte Growth Medium 2 (PromoCell, C-20011) plus supplements (PromoCell). 3 
Primary murine keratinocytes were isolated and cultured (Hager et al., 1999), with collagen 4 
IV-coated plates and CnT-PR medium (CELLnTEC, Bern, Switzerland). Confluent 5 
keratinocyte sheets seeded in 24-well plates were ‘scratch wounded’ and treated with 1 µg/ml 6 
MDP (Bachem, St Helens, UK) with or without 20 µg/µl mitomycin C (Sigma-Aldrich, Dorset, 7 
UK);  0-25 µg/ml mBD14; 1µg/ml Lipopolysaccharide (LPS); 1µg/ml Pam3-Cys; 107 CFU 8 
Staphylococcus aureus (SA); or 1µg/ml Peptidoglycan (PGN), for 24, 48 or 96 hours. Images 9 
were captured on a Nikon Eclipse E600 microscope (Nikon, Surrey, UK) and a SPOT insight 10 
camera (Image solutions Inc, Lancashire, UK). Scratch closure was quantified using Image Pro 11 
Plus software (Media Cybernetics, Cambridge, UK) averaged from fifteen measurements per 12 
sample. Calculations for percent closure were based on epithelial scratch width after specified 13 
duration (D), in relation to width at time zero (T0) using the equation ((T0-D)/T0)100).   14 
 15 
RNA isolation and reverse transcription-quantitative PCR (RT-qPCR) 16 
Total host RNA was isolated using the Purelink RNA kit (Invitrogen™ by Life Technologies 17 
Ltd, Paisley, UK). cDNA was transcribed from 1 µg of RNA (Promega RT Kit, Hampshire, 18 
UK and AMVreverse transcriptase, Roche, West Sussex, UK) and qPCR performed using the 19 
SYBR® Green 1 Kit (Eurogentec, Hampshire, UK) and an iCycler iQ quantitative PCR thermal 20 
cycler (Bio-Rad, Hertfordshire, UK). The primer sequences for real-time qPCR are listed in 21 
Table S1. 22 
 23 
DNA extraction from tissue samples and manipulation 24 
 14 
 
All tissue samples were incubated in enzymatic lysis buffer (20 mM Tris at pH 8.0, 0.2 mM 1 
EDTA, 1.2% triton X-100) and lysozyme (20 mg/ml) for 30 min at 37°C. DNA was extracted 2 
using a Qiagen DNeasy™ blood and tissue kit (Qiagen, West Sussex, UK).  3 
 4 
PCR amplification, purification and denaturing gradient gel electrophoresis (DGGE) 5 
The V3 variable region of the 16S rRNA gene was amplified from purified DNA by PCR using 6 
GC-rich eubacterium-specific primers P3_GC-341F and 518R (see Table S1) (Walter et al., 7 
2000) using a PTC-100 DNA Engine thermal cycler (Bio-Rad). Samples were purified using a 8 
Qiagen MinElute® purification kit (Qiagen). Polyacrylamide electrophoresis was performed 9 
using the D-CODE Universal Mutation Detection System (Bio-Rad). Denaturing gradient gels 10 
of 10% (wt/vol) acrylamide-bisacrylamide (37:1:5) were made as described previously (Walter 11 
et al., 2000). DGGE gel images were aligned and analyzed with BioNumerics software version 12 
4.6 (Applied Maths, Sint-Martens-Latem, Belgium) and profiles used to produce an 13 
Unweighted Pair Group Method with Arithmetic Mean (UPGMA) dendrogram.  14 
 15 
16S rRNA gene sequencing analysis 16 
16S amplicon sequencing targeting the V3 and V4 variable region of the 16S rRNA gene (Table 17 
S1) was performed on the Illumina MiSeq platform. The raw amplicon data was processed 18 
using quantitative insights into microbial ecology (QIIME) version 1.9.0 (Caporaso et al., 19 
2010), and R version 3.3.1 (Team, 2016). The NMDS plot was created using the isoMDS 20 
function in the ‘MASS’ package (Venables and Ripley, 2002) in R and statistical analysis 21 
performed using the ‘adonis’  function in the ‘vegan’ package in R. The Shannon Wiener 22 
Diversity Index was also calculated in R, using the ‘diversity’ function in the ‘vegan’ package 23 
(Okansen et al., 2016).  24 
 25 
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Hucker-Twort Gram Stain 1 
The Hucker-Twort Gram stain was used to distinguish Gram-positive and Gram-negative 2 
bacteria in formalin-fixed tissue. Slides were imaged using a 3D-Histech Pannoramic-250 3 
Flash Slide Scanner (3D Histech, Budapest, Hungary), using a 20x/0.25 Plan Apochromat 4 
objective (Zeiss, Oberkochen, Germany).  All tissue was blinded before analysis. The sum of 5 
scores for relative amounts of Gram-positive and Gram-negative bacteria in the wound bed 6 
tissue was quantified based on CMPT (Clinical Microbiology Proficiency-Testing) guidelines 7 
(score 0 to 4+), zero (score 0), rare or scant (score 1+), few (score 2+), moderate (score 3+) 8 
and many, numerous or heavy (score 4+) with regard to the numbers of organisms present per 9 
oil immersion field (x100).  10 
 11 
Animals and wounding 12 
Following local ethics committee approval, all animal studies were conducted in accordance 13 
with UK Home Office regulations. Mice were housed in isolator cages with ad libitum food 14 
and water. Wild-type (WT) (C57BL/6J) mice were bred from WTxWT matings and Defb14 15 
null mice (C57BL/6J background) were bred from heterozygous matings and have been 16 
described previously (Navid et al., 2012). Eight week-old female WT mice were anaesthetized 17 
and injected subcutaneously with 10 µg MDP (MurNAc-L-Ala-D-isoGin) (Bachem, UK, G-18 
1055) or vehicle (PBS), 24 hours and repeated 2 hours prior to wounding (n = 10 mice/group). 19 
Mice were anaesthetized and wounded following our established protocol (Ansell et al., 2014). 20 
Briefly, two equidistant 1 cm full-thickness incisional or 6 mm excisional wounds were made 21 
through both skin and panniculus carnosus muscle at the injection site and left to heal by 22 
secondary intention.  23 
 24 
Histology and immunohistochemistry (IHC) 25 
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Histological sections were prepared from tissue fixed in 10% buffered formalin saline and 1 
embedded in paraffin. 5 µM sections were stained with haematoxylin and eosin or subjected to 2 
IHC analysis using keratin 6, keratin 14 (Covance, Maidenhead, UK, PRB-169P and PRB-3 
155P); anti-Ki67 (Abcam, Cambridge, UK, ab16667); anti-neutrophil (Thermo Scientific, 4 
Runcorn, UK, MA1-40038); anti-Mac-3 (BD Biosciences, Oxford, UK, 553322); NOS2 (Santa 5 
Cruz Biotechnology, Heidelberg, Germany, SC-651); and arginase-I (Santa Cruz 6 
Biotechnology, SC-18354). Primary antibodies were detected using the appropriate 7 
biotinylated secondary antibody followed by ABC-peroxidase reagent (Vector Laboratories, 8 
Peterborough, UK, PK-6104 or PK-6101) with NovaRed substrate (Vector Laboratories, SK-9 
4800) and counterstained with haematoxylin. Images were captured using a Nikon Eclipse 10 
E600 microscope (Nikon) and a SPOT insight camera (Image solutions Inc). Total immune 11 
cell numbers (quantification is illustrated in figure S3), granulation tissue wound area and 12 
percentage re-epithelialization were quantified using Image Pro Plus software (Media 13 
Cybernetics).  14 
 15 
Minimum Inhibitory Concentrations (MIC)  16 
MICs were determined using the microdilution method (Moore et al., 2008). Briefly, an 17 
overnight culture of Pseudomonas aeruginosa (NCTC 10781) was diluted in sterile Mueller-18 
Hinton broth (Oxoid, Basingstoke, UK) to an OD600 of 0.5. The biologically active form of the 19 
mBD14 peptide (Reynolds et al., 2010),  20 
FLPKTLRKFFCRIRGGRCAVLNCLGKEEQIGRCSNSGRKCCRKKK (oxidized cysteines 21 
to form 3 disulfides) (Cambridge Peptides, Cambridge, UK), was serially diluted in inoculated 22 
media and incubated at 37°C for 24 hours with agitation. Growth was measured as light 23 
absorbance (495 nm) relative to un-inoculated and detected using a microtiter plate reader 24 
(Powerwave XS, Bio Tek Instruments, Potton, UK).  25 
 17 
 
 1 
Statistical analysis 2 
Normal distribution and statistical comparisons between groups were determined using 3 
Shapiro-Wilk test, Student’s t-test (two tailed), one or two-way ANOVA with Tukey post hoc 4 
test where appropriate using GraphPad Prism 7 Version 7.01 (GraphPad Software, Inc. La 5 
Jolla, CA) with the exception of the analysis for 16S rRNA gene sequencing analysis. For all 6 
statistical tests, the variance between each group was determined and probability values of less 7 
than P<0.05 were considered statistically significant.  8 
 9 
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FIGURE LEGENDS 23 
Figure 1. The microbiome profile of human DFUs is an indicator of healing outcome. DFU 24 
samples were collected at baseline and their wound microbial communities sequenced by 16S 25 
 25 
 
PCR-DGGE or 16S RNA Illumina high-throughput sequencing. Longitudinal healing was 1 
measured over the subsequent 12 weeks to define healing outcome. (a) UPGMA dendrogram 2 
of DFU DGGE fingerprints for healed (green) and non-healed (purple) wound tissue revealed 3 
clustering based on time to heal, ≥60% intrapersonal variation versus ≤30% interpersonal 4 
variation. (b) NMDS plot showing differences in clustering of microbial communities from 5 
16S RNA Illumina high-throughput sequencing and (c) diversity which was calculated using 6 
Shannon Weiner. (d-e) Taxonomic classification of the skin microbiome, showing proportion 7 
of bacteria, in each treatment group, at the phylum level and genus level. Individual taxa with 8 
abundances too low to visualise clearly and unassigned reads are grouped into the ‘other’ 9 
category, comprised of 12 additional phyla plus unassigned reads at the phylum level, and 225 10 
additional genera plus unassigned reads at the genus level. (f) Representative Gram stained 11 
histological sections and (g) quantification of numbers of bacteria per field of view. All data 12 
are representative of two independent experiments, with n = 19 patients for (a) and n = 25 for 13 
(b-g). * P<0.05. P values were determined by one-way ANOVA  (b-c); two-way ANOVA (d-14 
e) with Tukey post hoc test or by a paired, two-tailed Student’s t-test (g). Mean + s.e.m. Scale 15 
bar = 20 µm (f). 16 
 17 
Figure 2. Altered PRR expression in non-healing human DFUs. DFU samples were 18 
collected at baseline, with longitudinal healing measured over the subsequent 12 weeks. RT-19 
qPCR profiling of (a-e) TLR members and (f) NOD2 in patient wound samples collected at first 20 
visit with the patients subsequently categorized into either the healed wound group or the non-21 
healed wound group. (g) Representative crystal-violet stained human keratinocyte scratch 22 
wounds stimulated with 1 µg/ml MDP or control for 24 hours (dashed white line indicates 23 
initial scratch width; green line illustrates epidermal sheet edge measured) and (h) 24 
quantification of NHEK scratch closure in the presence or absence of mitomycin C.  (i) NOD2 25 
 26 
 
mRNA analyzed by qPCR. All data are representative of two-three independent experiments, 1 
with n = 19 patients in total (a-f), and n = 7-8 per treatment (g-i). * P<0.05. P values were 2 
determined by a non-parametric permutational multivariate analysis of variance in a, or paired, 3 
two-tailed Student’s t-test (b-i). Mean + s.e.m. Scale bar = 300 µm (g). 4 
 5 
Figure 3. Stimulation of the Nod2 pathway significantly delays murine cutaneous wound 6 
healing. (a) Representative IHC (keratin 14) of control or MDP injected incisional wounds 7 
(day 3), arrows denote wound margins. (b) Analysis of histological wound area and (c) re-8 
epithelialization. (d) Representative IHC of neutrophil and macrophages in control or MDP 9 
injected wounds at 3 days post-wounding, and quantification of (e) neutrophils and (f) 10 
macrophages (illustrated method figure S3). (g) Analysis of the distance contribution from the 11 
wound edge of keratin 6 expressing epidermal keratinocytes at 3 days post-wounding and (h) 12 
representative, keratin 6-stained images of control and MDP injected wounds at 3 days post-13 
wounding; arrows indicate the cessation of keratin 6 expression. (i) Quantification of the 14 
percent of basal keratinocytes expressing proliferation marker Ki67. Wound edge = 0-500µm 15 
from the wound and per-wound edge = 500-1000µm from the wound. (j) Representative Ki67 16 
staining, denoting location of wound and peri-wound edge. All data are representative of two-17 
three independent experiments with n = 6 mice/group. *** P<0.001, ** P<0.01, * P<0.05. P 18 
values were determined by paired, two-tailed Student’s t-test. Mean + s.e.m. Scale bar = 200 19 
µm (a, d), 50 µm (h,j). 20 
 21 
Figure 4. Nod2 stimulation alters defensin profile. qPCR analysis of cutaneous mBD1, 3 and 22 
14 or hBD1, 2 and 3 in control versus 1ug/ml MDP treated (a) wounds or (b) NHEKs. (c) 23 
Primary mouse keratinocyte monolayers were scratched and treated with 1, 10 or 25 μg/ml of 24 
mBD14 peptide and their closure assessed after 96 hours (dashed white line indicates initial 25 
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scratch width; green line illustrates epidermal sheet edge measured) (d). All data are 1 
representative of two-three independent experiments with n = 6 mice/group (a), and n = 7-8 2 
wells/dose (b-d). *** P<0.001, * P<0.05. P values were determined by paired, two-tailed 3 
Student’s t-test or one-way ANOVA for more than 2 groups. Mean + s.e.m.. 4 
 5 
Figure 5. Delayed healing in Defb14-deficient mice. Defb14-/- mice and littermate controls 6 
were excisionally wounded and analyzed three days post-wounding. (a) Representative 7 
hematoxylin and eosin stained sections of Defb14-/- excisional wounds (day 3), arrows indicate 8 
wound margins. Analysis of histological wound area (b), and re-epithelialization (c) at day 3 9 
post-wounding. Analysis of the distance contribution from the wound edge (d) and neo-10 
epidermal area (e) of keratin 6 expressing epidermal keratinocytes, illustrated in representative 11 
images of WT and Defb14-/- wounds at 3 days post-wounding (f); dashed outline indicates neo-12 
epidermal area. (g) Quantification of the percent of basal keratinocytes expressing proliferation 13 
marker Ki67. Wound edge = 0-500µm from the wound and per-wound edge = 500-1000µm 14 
from the wound. (j) Representative Ki67 staining, denoting location of wound and peri-wound 15 
edge. IHC quantification of (i) neutrophils and (j) macrophages. Further characterisation of 16 
macrophage polarisation looked at the proportion of (k) iNOS+ or (l) Arg1+ macrophages 17 
(illustrated method figure S3). All data are representative of two independent experiments with 18 
n = 5-6 mice/group. ** P <0.01, * P<0.05. P values were determined by paired, two-tailed 19 
Student’s t-test. Mean + s.e.m. Scale bar = 200 µm (a); 100 µm (f); 50 µm (h, i-l).  20 
 21 
Figure 6. Bacterial dysbiosis in Defb14-deficient mice. (a) Gram-stain of representative 22 
histological sections and (b) quantification reveals altered bacterial burden in Defb14-/- day 3 23 
wounds compared to control. (c) This is confirmed through RT-qPCR (eubacterial 16S) of total 24 
bacterial abundance which demonstrates a significant increase compared to WT littermate 25 
 28 
 
controls. These differences are associated with a significant increase of (d) P. aeruginosa, and 1 
(e) P. acnes as revealed by RT species-specific qPCR. All data are representative of two 2 
independent experiments with n = 5-6 mice/group. ** P<0.01, * P<0.05. P values were 3 
determined by paired, two-tailed Student’s t-test. Mean + s.e.m. Scale bar = 20 µm (a).   4 
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Supplementary Figure S1: Selective PRR activation in wound healing models. 
(a) PRR ligand treated HaCaT wound closure, 24hrs post scratch. Bacterial ligands = 
1µg/ml Lipopolysaccharide (LPS); 1µg/ml Pam3-Cys; 107 CFU Staphylococcus 
aureus (SA); 1µg/ml Peptidoglycan (PGN). (b-d) Expression of Nod2 (mRNA) and 
associated signalling components (Rip2 and Tak1) is significantly increased in MDP 
stimulated wounds compared to control at 3 days post-wounding. All data are 
representative of two-three independent experiments with n = 6 mice/group. ** 
P<0.01, * P<0.05. P values were determined by paired two-tailed Student’s t-test. 
Mean + s.e.m. 
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Supplementary Figure S2: Immune cell quantification method. (a) Approximately 5 x20 
images of immune cell immunohistochemical staining are captured to encompass the wound 
granulation tissue area. Scale bar = 200µm. (b) Red/brown positively stained cells are counted 
using the colour selection tool and area of granulation tissue measured (excluding epidermis, 
fat and muscle) using Image Pro software. Scale bar = 50µm. (c) Representative images are 
displayed at higher magnification enabling clear visualisation of cell staining. Scale bar = 
10µm. 
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Supplementary Figure S3: mBD14 peptide inhibits bacterial growth and 
keratinocyte migration in vitro. (a) mBD14 peptide was confirmed as biologically 
active using the MIC assay to assess P. aeruginosa growth. Data shows growth 
assay of Pseudomonas aeruginosa in the presence or absence of mBD14 peptide 
(25 µg/ml) (b) Primary human keratinocyte monolayers were scratched and treated 
with 1, 10 or 25 µg/ml of mBD14 peptide and their migration assessed after 48 hours. 
(c) hBD3 transfected and plasmid control HaCaT cell monolayers were scratched 
and closure assessed after 24hrs. *P<0.05 All data are representative of two-three 
independent experiments with n = 3-4 /group. 
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